GAITHERSBURG, Maryland
,
November 10, 2023
(press release)
–
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference. Conference Details: Fireside Chat Date: Wednesday, November 15, 2023 Time: 9:00 – 9:25 a.m. Greenwich Mean Time (GMT) Location: London Moderator: Roger Song, M.D., CFA, Equity Analyst Novavax participants: John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development Conference Event: Investor Meetings Date: Wednesday, November 15, 2023 Recordings About Novavax Please visit novavax.com and LinkedIn for more information. Contacts: Media SOURCE NOVAVAX, INC
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 45 days from the date of the conference.
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Ali Chartan
240-720-7804
media@novavax.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
